This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine


Brusa, Livia, Orlacchio, Antonio, Moschella, Vincenzo, Iani, Cesare, Bernardi, Giorgio, Mercuri, Nicola Biagio


Movement Disorders: Official Journal Of The Movement Disorder Society, Volume: 24, No.: 1, Pages.: 126-129

Year of Publication



Aripiprazole (AP), a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington’s disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington’s Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP’s therapeutic use.;

Bibtex Citation

@article{Brusa_2009, doi = {10.1002/mds.22376}, url = {}, year = 2009, month = {jan}, publisher = {Wiley-Blackwell}, volume = {24}, number = {1}, pages = {126--129}, author = {Livia Brusa and Antonio Orlacchio and Vincenzo Moschella and Cesare Iani and Giorgio Bernardi and Nicola Biagio Mercuri}, title = {Treatment of the symptoms of Huntington{textquotesingle}s disease: Preliminary results comparing aripiprazole and tetrabenazine}, journal = {Movement Disorders} }


adult, adverse, adverse effects, aged, aripiprazole, chemically induced, dopamine agents, drug effects, drug therapy, dyskinesia druginduced, effects, female, genetics, humans, huntington disease, hyperkinesis, male, middle aged, nerve tissue proteins, nuclear proteins, piperazines, prevention & control, quinolones, receptors dopamine d2, tetrabenazine, therapeutic use, trinucleotide repeats

Countries of Study


Types of Dementia


Types of Study

Cohort Study

Type of Outcomes

Depression and Anxiety, Other

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime, Other